Myriad Genetics (MYGN) Stock Sinks As Revenue Reset Deepens Loss Fears

Myriad Genetics came into this earnings print already under pressure, with the stock down sharply over the past quarter. Today’s nearly 47% single day slump indicates that sentiment has cracked further, but the numbers behind that move center on one thing. The headline is a revenue reset in a business that still runs at a loss.

Q2 revenue of US$190.7m fell against last year and management cut full year 2026 sales guidance to US$770m to US$790m, while suspending adjusted earnings guidance. For a diagnostics stock built on a long term genomics thesis, the immediate story is now about pricing, payers and the timing of potential profitability.

Is Myriad Genetics now a genuine bargain on just 0.3x sales, or is the low multiple simply pricing in persistent losses and volatility? See how NasdaqGS:MYGN stacks up in our valuation analysis for Myriad Genetics

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$190.7m vs. US$213.1m (declined 11%)
• Net Loss, Q2 2026 vs. Q2 2025: US$34.1m vs. US$330.5m (loss narrowed significantly)
• Basic EPS, Q2 2026 vs. Q2 2025: loss of US$0.25 per share vs. loss of US$3.57 per share (loss per share narrowed significantly)
• Products Launched, Q2 2026 vs. Q2 2025: 1 vs. 0 (new product introduction in the current quarter)

Prefer clear charts instead of another wall of earnings tables and guidance cuts? See Myriad Genetics’ full financial picture, including how analysts are modeling its path toward profitability, in our interactive company report for Myriad Genetics.

Evaluating Whether Myriad’s Oncology Pivot Is Delivering

The bullish story on Myriad Genetics rests on it becoming a precision oncology leader with improving adoption, reimbursement and margins. On clinical and product milestones, the quarter moved that story forward. MyRisk hereditary cancer volumes grew 10% and Myriad expanded its Precise MRD minimal residual disease offering into colorectal and renal cancers while pushing breast cancer coverage to MolDX, the Medicare program that sets molecular diagnostics policy. Prolaris+ AI, the prostate cancer test that builds on the recently published large meta analysis, launched with early customer interest, which supports the idea that Myriad’s oncology menu is getting broader and more clinically relevant.

Where the bullish narrative struggles is on the economic side. Average revenue per test weakened, gross margin guidance stepped down to 66% to 67% and full year revenue guidance was cut by about US$90m. Operational traction in oncology is not yet translating into the cleaner reimbursement and margin profile that thesis assumes.

Compare Myriad Genetics’ internal progress on oncology testing and AI driven products with how institutional analysts are reacting to the 46.74% share price drop and reset guidance, and see whether the Street views this as the start of a credible turnaround or a value trap by checking the consensus price target analysis for Myriad Genetics.

Myriad Genetics Bears See Revenue Quality Concerns Confirmed

The bearish view on Myriad Genetics argues that payer pushback, competitive pressure and weak margins could lock the business into prolonged losses. This quarter largely supports that concern. Revenue fell 11% year on year to US$190.7m even though volumes were roughly flat, which means the hit came mainly from pricing and reimbursement. Average revenue per test weakened, and management cut full year 2026 sales guidance to US$770m to US$790m while also trimming gross margin guidance to 66% to 67%.

Bears also worry about margin and profitability uncertainty. Here too the milestones were missed. Myriad reported an adjusted EBITDA loss of US$16.9m and suspended full year adjusted EBITDA guidance after restructuring moves, rather than gaining visibility. Management explicitly assumes no improvement in average revenue per test for the rest of 2026. This signals that payer friction and pricing pressure remain unresolved for now.

After a revenue reset of this size, it is fair to ask if management issues and payer friction are just early warning signs. Review the risk analysis for Myriad Genetics which shows 2 important warning signs

Stay Ahead Of Your Next Move

If the revenue reset and sharp share price fall at Myriad Genetics has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how the thesis evolves. Once you decide to take a position, use the Portfolio Command Center to cut through noise and keep on top of only the most important updates to your holdings. For a wider view on how other investors are thinking about Myriad Genetics and similar stocks, turn to the Community for crowd insights and debate. By spotting potential catalysts and risks early, you give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond Myriad Genetics?

Fresh ideas move first. Stocks with early breakout potential rarely stay under the radar for long and momentum can be caught or missed in days. Scan these curated shortlists and act now.

• Spot companies building steady momentum and strong cash generation by reviewing the curated 55 high quality undervalued stocks before they stop looking cheap to the wider market.
• Track the next wave of infrastructure plays supporting AI demand by checking the hand picked 55 AI infrastructure stocks while they are still flying under most radars.
• Follow the cash rich operators tied to future energy spending by scanning the focused 35 power grid technology and infrastructure stocks before potential growth stories are fully priced in.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com